Estela Rodriguez: Discussion on best 1st line therapy for ALK+ NSCLC at MATOS24
Estela Rodriguez, Associate Director of Community Outreach and Co-Lead of Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, shared a post on X:
“MATOS24 Panel of experts discussing best 1st line therapy for ALK+ NSCLC– preferred choice lorlatinib but a lot of discussion of managing toxicities, dose reduction and shared decision making with patients.”
Estela (Estelamari) Rodriguez is Associate Director of Community Outreach and Co-Lead of Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. She is board certified in medical oncology and hematology. She has a special interest in the early detection of lung cancer and increasing access to clinical trials.
For more Updates, Follow OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023